# Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia

> **NCT06047262** · PHASE2 · RECRUITING · sponsor: **Marc Donath** · enrollment: 300 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Dapansutrile
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06047262
- **Lead sponsor:** Marc Donath
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-09
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06047262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06047262, "Dapansutrile in Diabetes and Diabetes-Related Complications - Dapan-Dia". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06047262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*